A PHASE II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. 2) Patients with NSCLC of mixed histology (squamous and non-squamous) are eligible, and must be classified on the basis of the major histological component (non-squamous or squamous). 3) Patients may be screened based on clinical stage, but mandatory preoperative documentation of N2 nodal involvement by invasive mediastinal staging (e.g., CT-guided biopsy, endobronchial ultrasound, mediastinoscopy) is required for PET-positive N2 nodes.

You may not be eligible for this study if the following are true:

  • 1) NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified and small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC. 2) Any prior therapy for lung cancer, including immunotherapy, chemotherapy, or radiotherapy. 3) Active or history of autoimmune disease or immune deficiency. 4) NSCLC with an activating EGFR mutation or ALK fusion oncogene.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.